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A new property of ursolic acid, lipoxygenasc and cyclooxygcnase inhibition, has been described in an acetonr-extract of heather flowers (Cufluna 
vulgnris) which could help explain Ihe an&inRammatory characteristics of this plani. In mouse periton& macrophagcs, human platelets and 
differentiated HL60 leukemic ells, ursolic acid, at I PM. blocks arachidonate metabolism. 
Lipoxygenasc; Arachidonic acid; Cyclooxygenasr; Ursolic acid; Cduna v&m% 
1. INTRODUCTION 2.3. Plufr r lipos~gerkw ~tssq~ 
The prcparatlon of potato tuber 5-lipoxygcnase (S-LOX) has been 
described [6]. Soybean lipoxygcnase was from Sigma. Acdvity of both 
enzymes was assayed with linoleic acid (Sigma) as the subsirate under 
the conditions previously described [7, S]. Briefly, lipoxygenasc activ- 
ity was tested by measuring oxygen consumption using a Clark- 
oxygen electrode with a Gilson oxygraph assuming a 240 PM 0: 
concentration in air-saturaied buffer at ZSpC. The standard assay 
mixtures contained potato 5.LOX in 0.2 M sodium acetate (pH 5.6) 
or soybean IS-lipoxygenase (IS.LOX) in 200 mM phosphate buffer 
(pH 7.4). The reaclion was started by the addhion of linolcicacid using 
Michaelis saturalion conditions for each enzyme. 
Although flowers of the plant, Cuilunu &gul’is, have 
been used for centuries in the treatment of inflam- 
matory diseases [l, 21, its mode of action is unknown. 
Since arachidonic acid metabolites are important me- 
diators of inflammation, especially the products of the 
lipoxygenase pathway [3, 41, we used lipoxygenase in- 
hibition as a test to screen several heather flower ex- 
tracts. This test allowed us to purify and characterize 
ursolic acid as the agent responsible for the inhibition 
of lipoxygenase activity in the acetone extract. In this 
paper, we describe for the first time, its biological effect 
on arachidonic acid metabolism in mo,use peritoneal 
macrophages, human platelets and differentiated HL60 
leukemic cells (used as a model of polymorphonuclear 
leukocytes) and we compare it to the classical ipo- 
xygenase and cyclooxygenase inhibitors, NDGA, 
BW755C and caffeic acid. 
2. MATERIALS AND METHODS 
2. I. l,solaliorr urtd purifcutiorr of ursoiic ocid 
Cdhmu wrlgaris flowers collected in August-September 1990, in the 
Man&i&s country-side, Corr&e, France (collection data no. 101) 
were extracted with acetone. Dry residue was !oaded on a LH2, Sc- 
phadex column (eluted by CH,OH with a gradient of CHCI,). Frac- 
tions inhibiting lipoxygenasc aclivity were pooled and pkfied on a 
silicic acid column (CHCI,/CHI\OH: 9713. v/v) and analyzed by 
GC:MS and ‘Ii and “C NMR. The determinalion of the ursolic acid 
X-ray crystallographic structure is described elsewhere [5]. 
Ctit~~q’r’~&~~e a&!~rss: A. Najid, C!F INSER?.! 88-03. FncUltC de 
MCdecinc, UniversitC dc Limogcs. 2 rue Dr. Marcland, 87025 
Limoges, France. Fah: (33) 55 50 I1 84. 
Careic acid (3,4-dihydroxycinnamic acid) and NDGA (nordihy- 
droguaiaretic acid) were from Aldrich. BW7SSC (3-amino-l-[rrt-(tri- 
fluoromelhyl)-phenyl]-2.pyrazoline) was a gill from Wcllcome 
Research Laboratories, Langley Court. Bcckenham. L’K). 
1.4, Aruchidonic acid ~m!tuholisn~ by I~~SL’ prri~uneui rrtucroplrcg~s 
Resident macrophages from Swiss mice were incubated with 
[“C]arachidonic acid as previously described [9]. Briefly, peritoneal 
cells from 57 mice were collected by washing the peritoneal cavity with 
10 ml of icecold RPMI-I600 with a syringe containing 10 U/ml hep. 
arin. Peritoneal cells wcrc then distributed and incubated at 37’C in 
six I75 cm2 flasks in 50 ml of RPMI-1640 supplfmenled with l&al calf 
serum (5%), glulamine (4 mM). penicillin (3!?0 U), streptomycin (200 
pg/ml) and gentamycin (50 p&nl). After allowing macrophages to 
Fig. I. Formula of ursolic acid. 
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Fig. 7. Ursalic acid cytotoxicity assays. (A) The figure shows that cell viability, after 48 h treatment with 0.01-IOpM ofursolic acid, was greater 
than 90% as measured by the Trypan blue exclusion test as well as the reduction of MTT (8). The uraolic acid toxicity to the HL60 cells was observed 
only at the highest concentration used (IO0 PM). 
adhere (2 h at 37C). non-adherent cells were discarded and flasks 
were placed at 0°C on ice for I h. Viable macrophages (71 x IO’) were 
recuperated, resuspended in 2 ml RPMI-1640 and incubated for 30 
min with either ursolic acid (I PM), NDGA (1 PM). BW75SC (I j!M) 
or caffeic acid (I PM) at 37°C in a shaking water-bath. They were then 
incubated wirh [“C]arachidonic acid (0.1 PCi, Amersham) for IO min, 
Fig. 3. Arachidonic acid metabolism by mouse peritoneal macrohages (B), human platelets (C) and leu!;emic HL60 CCY:S (D). (A), arachidonic 
incubated without cells (control); FL. phospholipids; AA, arachidonic acid; Ch.A.4. cholestcrol.arachidonatc; TX, thr)mboxane; PG. ptosta- 
glandins; HETEs, hydroxyeicosatetraenoic acids: HHT, l2-hydroxy-5,8,!0-hepladecatrienoic a&. 
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the suspension acidified to pH 3 (citric acid, 2 M) and extracted twice 
with 5 ml of dicthyl ether and once with 5 ml of ethylacetate, Lipid 
extracts were evaporated to dryness under a nitrogen stream and 
submitted to thin-layer chromatography (Silica gel 60 (20 x 20 cm, 0.25 
mm), Merck). An aliquot (200~1) of this extract was applied to a TLC 
plate under a nitrogen stream, together with a known slandard solu- 
tion, containing 5-HETE, IZHETE, IS-HETE, prostaglanlins 
(PGA2, PGD:, PGE.. PGFz,, and 6-keto-PGF,,), and thromboxanc 
B, (TxB&. The solvent system [lo] consisted ofcthyl acetate/isoocUne/ 
acetic acid/water (I 1:5:2:10, v/v, organic phase). After visualization of 
standards with iodine vapour, the radioactive metabolites were dc- 
tccted using a Bcrthold scanner. 
2.5. Amchidonic acid rwtabolisrtt by kurrrar~ platelets 
Human platelets were prepared from healthy donors who had 
received no aspirin-like compounds during the preceding 4 weeks. 
Blood was collected in 0.15 volume of anticoagulant, citrate dextrose. 
and ccntrifugcd for 20 min at 300 x g at room tempera:urc: the 
platelet-rich plasma (PRP) was recovered. After addition of EDTA to 
a Rnal concentration of I mM, the PRP was cooled to 0°C and 
centrifuged at 2,000 x g for 20 min. Arachidonic acid metabolism was 
analyzed as described above for macrophages. 
HL60 cells were maintained in liquid culture RPMI-1640 medium 
supplemented with 10% fetal bovine serum, 4 PM L-glutaminc, 100 
pg/ml streptomycin and 100 U/ml of penicillin (Gibco). For dif- 
ferentiation studies, cells from log phase cultures were diluted to IO’ 
ccllslml and cultured for 5 days. Cells were induced to granulocytic 
differentiation by the addition of DMSO(Merck) at the timcofplating 
at 3 final concentration of I .3%. The arachidonic acid metabolism was 
analyzed as described above for macrophagcs, 
The MTT colorimctric assay was made as described by Mosmann 
[ 131. This test is based upon the wlcctive ability of living cells to reduce 
the yellow soluble salt, MTT (3-[4,5-dimcthymthiazol-2-y&2,5 di- 
phenyl tetrazolium bromide), to a purple-blue insoluble fomavln 
precipitate. Experiments were performed in quadriplicate in3 24-well 
culture plate (Falcon). MTT (Sigma) was dissolved in PBS at 5 m@ml. 
After 48 h incubation of HL60 with ursolic acid, stock MTT solution 
(200~1 per 2 ml medium) was added to all wells of an &my, and plates 
were incubated 3137°C for 4 II. After addition of2 ml of0.04 N HCL 
in isopropanol, the optical density of the medium was read at 570 nm. 
3. RESULTS AND DISCUSSION 
In an effort to find naturally occuring anti-lipo- 
xygenase compounds, several organic or aqueous 
heather flower extracts were screened for t&r ability to 
inhibit lipoxygenase activity. Among them, the acetone 
extract was further analyzed. Thus, we purified and 
characterized ursolic acid (Fig. 1). and determined its 
X-ray crystallographic structure: this latter showed us 
that ursolic acid adopts chair conformations [S]. Fig. 2 
shows that cell viability, after 48 h treatment with O.Ol- 
10 @I of ursolic acid, was greater than 90% as 
measured by the Trypan blue exclusion test (Fig. 2A) 
as well as the reducton of MTT (Fig. 2B). The ursolic 
acid toxicity to the ML60 cells was observed only at the 
highest concentration used (100 yM). 
J.d-I-...L...L- 
:; . h A 
1 NDGA ( 1pM) 
Urslic ncid ( IpM) 
! 
Fig. 4. Elf&s of NDGA (A), BW71i5C (6). ursolic acid (C) and caffcic acid (D) on mouse peritoneal macrophages arachidonic acid metabolism. 
Pi-, phospholipids; AA, arachidonic acid; Ch.AA, cholesterol-arachidonate; TX. thromboxanc; PG. prostaglandins; HETEs, hydroxyeicosate- 
tracnoic acids. 
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Fig. 5. Effccu of NDGA (A). BW755C (B) and ursolic acid (C) on human platelet (A&C) and ursolic acid (D) on difkrentioted HL60 cells(D) 
arachidonic acid metabolism. PL. phospholipids; AA, arachidonic acid; Ch.AA. cholesterol-arachidonate; TX,thromboxane; PG, prostaglandin: 
HETE. hydroxyeicosatetraenoic acid; HHT, 13hydroxy-5,8,10-heptadecnttienoic acid. 
Using radiochromatographic procedures and blood 
cells, we investigated the direct er”fects of ursolic acid on 
arachidonic acid metabolism in comparison with classi- 
cal lipoxygenase and cyclooxygenase inhibitors. The 
TLC profiles obtained for [“Clarachidonic acid metab- 
olism by blood cells are shown in Fig. 3. The 12. and 
15.HETEs reference standards could not be separated 
with the TLC system used. Addition of I PM ursolic 
acid to the reaction mixture decreased the formation of 
the lipoxygenase and cyclooxygenase products in all 
tested cells. In macrophages, ursolic acid (1 PM) in- 
hibited the 5-LOX metabolism of arachidonic acid to a 
much greater extent than that of 12- and 15-LOX (re- 
spectively, 80 and 60%, Fig. 4). Cyclooxygenase activity 
was inhibited by 38%. The comparison with the classical 
lipoxygenase inhibitors (phenolic antioxidants uch as 
NDGA, BW755C and naturally occuring phenolic 
caffeic acid) showed that ursolic acid was significantly 
,!es; Inhibitory than NDGA and BW755C on the forma- 
tion of LOX and CO (cyclooxygenase) products in mac- 
rophages, but it was more effective than caffeic acid 
(Fig, 4). In contrast, the effect of ursolic acid and 
BW’155C on the formation of LOX and CO products in 
platelets was more pronounced than that of NDGA 
(Fig. 5). Ursolic acid also inhibited arachidonic acid 
metabolism in differentiated HL60 leukemic ells (used 
here as a model of granulocytes): the level of 5-HETE 
was diminished by 86%, 15.HETE by 59% and prosta- 
glandins by 50% (Fig. 5). 
Ursolic acid has never been related to lipoxygenase 
biochemistry before. Its effect appears to be dependent 
upon cell type (macrophage, platelet or granuiocyte), 
but it affected the level of arachidonic acid metabolites 
in all tested celts. 
During preparation of this manuscript, Ying es al. 
[l l] described the inhibition of human leucocyte lastase 
by ursolic acid. Since elastase is a lysosomal proteinase 
stored in leucocytes and responsible for tissue destruc- 
tion in rheumatoid arthritis [12] 2nd since arachidonic 
acid metabolites are among the mediators associated 
with perpetuating inflammatory processes, ursolic acid 
could be considered as a potential naturally occuring 
antI-inflanuaatory agent. Our results, combined with 
those or’ Y ing et al. [ 111, probably demystify the belief 
in czrtain aspects of the u- p- of Calluna vulgaris in folk 
medicine [I, 21. 
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